Dementia New Drug R&D
Charsire is committed to develop topical new drugs to address unmet needs in brain and aging diseases. Our new drug BAC for Alzheimer’s disease and vascular dementia has completed the Phase II clinical trial of the US Food and Drug Administration (FDA). Subsequent developments are underway. In addition, we have completed the clinical trials of diabetic foot ulcers and cancer radiodermatitis, and obtained the approval of Taiwan’s Class II medical device.